CD22: B-cell receptor CD22
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow.
- Drugs that act on it: 13
- Approved: 2
- In phases 1 to 3: 10
- Sponsors: 7
Who Is On It, and How Far Along
Every drug ChEMBL records acting on CD22, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody
- Antibody-drug conjugate
- Other
Approved2
Phase 34
Phase 23
Phase 13
Preclinical or unknown1
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Gilead Sciences215%
- BeOne Medicines18%
- Innate Pharma18%
- MedImmune LLC18%
- Pfizer18%
- Roche18%
- UCB Pharma18%
Modalities
Drugs on this target by ChEMBL molecule type.
- Antibody646%
- Antibody-drug conjugate431%
- Other323%
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 9 of 13 act as: CD22 binding agent; the rest name their own mechanism.| Inotuzumab ozogamicin | Approved | Pfizer | Antibody-drug conjugate | Binding agent | — | 38 | Boxed warning |
| Moxetumomab pasudotox | Approved | Innate Pharma | Antibody-drug conjugate | Binding agent | — | 1 | Boxed warning |
| Inotuzumab | Phase 3 | BeOne Medicines | Antibody | Binding agent | — | 38 | — |
| Epratuzumab | Phase 3 | UCB Pharma | Antibody | Inhibitor | CD22 inhibitor | 1 | — |
| Bectumomab | Phase 3 | — | Antibody | Other | CD22 other | 0 | — |
| Epratuzumab 90Y | Phase 3 | Gilead Sciences | Antibody | Binding agent | — | 0 | — |
| BL22 | Phase 2 | MedImmune LLC | Other | Binding agent | — | 0 | — |
| Pinatuzumab vedotin | Phase 2 | Roche | Antibody-drug conjugate | Binding agent | — | 0 | — |
| Yttrium y 90 epratuzumab tetraxetan | Phase 2 | Gilead Sciences | Antibody | Inhibitor | CD22 inhibitor | 0 | — |
| Epratuzumab-cys-tesirine | Phase 1 | — | Antibody-drug conjugate | Binding agent | B-cell receptor CD22 binding agent | 0 | — |
| MONO-DGA-RFB4 | Phase 1 | — | Other | Binding agent | — | 0 | — |
| Yttrium y 90 epratuzumab | Phase 1 | — | Antibody | Binding agent | — | 0 | — |
| IMMURAIT-LL2 | Preclinical or unknown | — | Other | Binding agent | — | 0 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 10 in all, from ClinicalTrials.gov.Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Neoplasm
- 0.49
- Precursor B-cell acute lymphoblastic leukemia
- 0.30
- Lymphoma
- 0.30
- Sjogren syndrome
- 0.26
- Mixed phenotype acute leukemia
- 0.26
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3218, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P20273, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets